|
EP3608308B1
(en)
*
|
2013-03-08 |
2021-07-21 |
Novartis AG |
Lipids and lipid compositions for the delivery of active agents
|
|
JP6694811B2
(ja)
|
2013-10-04 |
2020-05-20 |
ノバルティス アーゲー |
ＲＮＡ干渉に使用するためのＲＮＡｉ剤用の３’末端キャップ
|
|
EP3052107B1
(en)
|
2013-10-04 |
2018-05-02 |
Novartis AG |
Organic compounds to treat hepatitis b virus
|
|
EP3052627B1
(en)
|
2013-10-04 |
2018-08-22 |
Novartis AG |
Novel formats for organic compounds for use in rna interference
|
|
CN106061466A
(zh)
*
|
2013-12-19 |
2016-10-26 |
诺华股份有限公司 |
瘦蛋白mRNA组合物和制剂
|
|
SG10201912038TA
(en)
|
2014-04-23 |
2020-02-27 |
Modernatx Inc |
Nucleic acid vaccines
|
|
EP3169309B1
(en)
*
|
2014-07-16 |
2023-05-10 |
Novartis AG |
Method of encapsulating a nucleic acid in a lipid nanoparticle host
|
|
EP3200792A4
(en)
*
|
2014-10-03 |
2018-05-09 |
The Institute for Cancer Research d/b/a The Research Institute of Fox Chase Cancer Center |
Poly (adp-ribose) polymerase 1 inhibitors structurally unrelated to nad
|
|
US10264976B2
(en)
|
2014-12-26 |
2019-04-23 |
The University Of Akron |
Biocompatible flavonoid compounds for organelle and cell imaging
|
|
US10792299B2
(en)
|
2014-12-26 |
2020-10-06 |
Nitto Denko Corporation |
Methods and compositions for treating malignant tumors associated with kras mutation
|
|
US20180002702A1
(en)
|
2014-12-26 |
2018-01-04 |
Nitto Denko Corporation |
Methods and compositions for treating malignant tumors associated with kras mutation
|
|
EP3324979B1
(en)
|
2015-07-21 |
2022-10-12 |
ModernaTX, Inc. |
Infectious disease vaccines
|
|
WO2017020026A1
(en)
|
2015-07-30 |
2017-02-02 |
Modernatx, Inc. |
Concatemeric peptide epitopes rnas
|
|
KR102630720B1
(ko)
|
2015-08-28 |
2024-01-29 |
세키스이 메디칼 가부시키가이샤 |
벤질 화합물
|
|
GB201518172D0
(en)
*
|
2015-10-14 |
2015-11-25 |
Cantab Biopharmaceuticals Patents Ltd |
Colloidal particles for use in medicine
|
|
TW201729835A
(zh)
|
2015-10-22 |
2017-09-01 |
現代公司 |
呼吸道病毒疫苗
|
|
EP3364949A4
(en)
|
2015-10-22 |
2019-07-31 |
ModernaTX, Inc. |
CANCER VACCINES
|
|
CA3002912A1
(en)
*
|
2015-10-22 |
2017-04-27 |
Modernatx, Inc. |
Nucleic acid vaccines for varicella zoster virus (vzv)
|
|
KR102860636B1
(ko)
|
2015-12-28 |
2025-09-17 |
노파르티스 아게 |
혈색소병증의 치료를 위한 조성물 및 방법
|
|
TWI773666B
(zh)
|
2016-03-30 |
2022-08-11 |
美商英特利亞醫療公司 |
Crispr/cas 組分之脂質奈米粒子調配物
|
|
EP3445375A1
(en)
|
2016-04-22 |
2019-02-27 |
Intellia Therapeutics, Inc. |
Compositions and methods for treatment of diseases associated with trinucleotide repeats in transcription factor four
|
|
KR102469450B1
(ko)
|
2016-05-18 |
2022-11-22 |
모더나티엑스, 인크. |
인터류킨-12 (il12)를 코딩하는 폴리뉴클레오티드 및 그의 용도
|
|
WO2017201352A1
(en)
|
2016-05-18 |
2017-11-23 |
Modernatx, Inc. |
Mrna combination therapy for the treatment of cancer
|
|
US10967057B2
(en)
|
2016-06-02 |
2021-04-06 |
Glaxosmithkline Biologicals S.A. |
Zika viral antigen constructs
|
|
WO2018029586A1
(en)
|
2016-08-07 |
2018-02-15 |
Novartis Ag |
Mrna-mediated immunization methods
|
|
EP3518966A1
(en)
|
2016-09-29 |
2019-08-07 |
GlaxoSmithKline Biologicals S.A. |
Compositions and methods of treatment of persistent hpv infection
|
|
GB201616904D0
(en)
|
2016-10-05 |
2016-11-16 |
Glaxosmithkline Biologicals Sa |
Vaccine
|
|
US12491261B2
(en)
|
2016-10-26 |
2025-12-09 |
Acuitas Therapeutics, Inc. |
Lipid nanoparticle formulations
|
|
ES3063077T3
(en)
|
2016-10-26 |
2026-04-15 |
Acuitas Therapeutics Inc |
Lipid nanoparticle formulations
|
|
WO2018089851A2
(en)
|
2016-11-11 |
2018-05-17 |
Modernatx, Inc. |
Influenza vaccine
|
|
BE1025121B1
(fr)
|
2016-11-17 |
2018-11-05 |
Glaxosmithkline Biologicals Sa |
Constructions antigeniques du virus zika
|
|
WO2018096405A1
(en)
*
|
2016-11-28 |
2018-05-31 |
Cellix Bio Private Limited |
Compositions and methods for the treatment of oral infectious diseases
|
|
AU2017379073B2
(en)
*
|
2016-12-22 |
2023-12-14 |
Intellia Therapeutics, Inc. |
Compositions and methods for treating alpha-1 antitrypsin deficiency
|
|
KR102442753B1
(ko)
*
|
2016-12-26 |
2022-09-16 |
셀릭스 바이오 프라이빗 리미티드 |
만성 통증 치료를 위한 화합물
|
|
TW201839136A
(zh)
|
2017-02-06 |
2018-11-01 |
瑞士商諾華公司 |
治療血色素異常症之組合物及方法
|
|
WO2018170245A1
(en)
|
2017-03-15 |
2018-09-20 |
Modernatx, Inc. |
Broad spectrum influenza virus vaccine
|
|
EP3595713A4
(en)
|
2017-03-15 |
2021-01-13 |
ModernaTX, Inc. |
RESPIRATORY SYNCYTIAL VIRUS Vaccine
|
|
WO2018187590A1
(en)
|
2017-04-05 |
2018-10-11 |
Modernatx, Inc. |
Reduction or elimination of immune responses to non-intravenous, e.g., subcutaneously administered therapeutic proteins
|
|
EP3461497A1
(en)
|
2017-09-27 |
2019-04-03 |
GlaxoSmithKline Biologicals S.A. |
Viral antigens
|
|
AR113154A1
(es)
|
2017-09-29 |
2020-01-29 |
Intellia Therapeutics Inc |
Polinucleótidos, composiciones y métodos para edición del genoma
|
|
EP3688161A1
(en)
|
2017-09-29 |
2020-08-05 |
Intellia Therapeutics, Inc. |
Compositions and methods for ttr gene editing and treating attr amyloidosis
|
|
BR112020006256A2
(pt)
|
2017-09-29 |
2020-10-20 |
Intellia Therapeutics, Inc. |
método in vitro de administração de mrna usando nanopartículas de lipídio
|
|
PT3688162T
(pt)
|
2017-09-29 |
2024-04-23 |
Intellia Therapeutics Inc |
Formulações
|
|
WO2019148101A1
(en)
|
2018-01-29 |
2019-08-01 |
Modernatx, Inc. |
Rsv rna vaccines
|
|
EP3836963A2
(en)
|
2018-08-17 |
2021-06-23 |
GlaxoSmithKline Biologicals S.A. |
Immunogenic compositions and uses thereof
|
|
WO2020072605A1
(en)
|
2018-10-02 |
2020-04-09 |
Intellia Therapeutics, Inc. |
Ionizable amine lipids
|
|
JP2022512703A
(ja)
|
2018-10-16 |
2022-02-07 |
インテリア セラピューティクス，インコーポレイテッド |
免疫療法のための組成物および方法
|
|
JP7543259B2
(ja)
|
2018-10-18 |
2024-09-02 |
アクイタス セラピューティクス インコーポレイテッド |
活性剤の脂質ナノ粒子送達のための脂質
|
|
AU2019361203B2
(en)
|
2018-10-18 |
2026-03-26 |
Intellia Therapeutics, Inc. |
Compositions and methods for transgene expression from an albumin locus
|
|
US20200268906A1
(en)
|
2018-10-18 |
2020-08-27 |
Intellia Therapeutics, Inc. |
Nucleic acid constructs and methods of use
|
|
JP7578590B2
(ja)
|
2018-10-18 |
2024-11-06 |
インテリア セラピューティクス，インコーポレーテッド |
第ｉｘ因子を発現するための組成物及び方法
|
|
AU2019361204A1
(en)
|
2018-10-18 |
2021-05-27 |
Intellia Therapeutics, Inc. |
Compositions and methods for treating alpha-1 antitrypsin deficiencey
|
|
IL314386A
(en)
|
2018-12-05 |
2024-09-01 |
Intellia Therapeutics Inc |
amine modified lipids
|
|
EP3938379A4
(en)
|
2019-03-15 |
2023-02-22 |
ModernaTX, Inc. |
Hiv rna vaccines
|
|
AU2020248337A1
(en)
|
2019-03-28 |
2021-11-04 |
Intellia Therapeutics, Inc. |
Compositions and methods for ttr gene editing and treating ATTR amyloidosis comprising a corticosteroid or use thereof
|
|
EP3946598A1
(en)
|
2019-03-28 |
2022-02-09 |
Intellia Therapeutics, Inc. |
Compositions and methods comprising a ttr guide rna and a polynucleotide encoding an rna-guided dna binding agent
|
|
BR112021019224A2
(pt)
|
2019-03-28 |
2021-11-30 |
Intellia Therapeutics Inc |
Polinucleotídeos, composições e métodos para expressão de polipeptídeo
|
|
WO2020219876A1
(en)
|
2019-04-25 |
2020-10-29 |
Intellia Therapeutics, Inc. |
Ionizable amine lipids and lipid nanoparticles
|
|
WO2020252455A1
(en)
|
2019-06-13 |
2020-12-17 |
The General Hospital Corporation |
Engineered human-endogenous virus-like particles and methods of use thereof for delivery to cells
|
|
WO2021016075A1
(en)
|
2019-07-19 |
2021-01-28 |
Flagship Pioneering Innovations Vi, Llc |
Recombinase compositions and methods of use
|
|
KR20220035457A
(ko)
|
2019-07-21 |
2022-03-22 |
글락소스미스클라인 바이오로지칼즈 에스.에이. |
치료 바이러스 백신
|
|
US12569438B2
(en)
|
2019-07-29 |
2026-03-10 |
Georgia Tech Research Corporation |
Nanomaterials containing constrained lipids and uses thereof
|
|
CA3146607A1
(en)
|
2019-09-01 |
2021-03-04 |
Joseph Yeshayahu KLEIN |
Cannabinoid containing targeting liposomes
|
|
AU2020397956A1
(en)
|
2019-12-04 |
2022-07-07 |
Orna Therapeutics, Inc. |
Circular RNA compositions and methods
|
|
CN115176005A
(zh)
|
2019-12-18 |
2022-10-11 |
诺华股份有限公司 |
用于治疗血红蛋白病的组合物和方法
|
|
US12435035B2
(en)
|
2020-01-09 |
2025-10-07 |
Guide Therapeutics, Llc |
Nanomaterials
|
|
IL296024A
(en)
|
2020-03-04 |
2022-10-01 |
Flagship Pioneering Innovations Vi Llc |
Methods and compositions for modulating a genome
|
|
WO2021209970A1
(en)
|
2020-04-16 |
2021-10-21 |
Glaxosmithkline Biologicals Sa |
Sars cov-2 spike protein construct
|
|
KR20230017783A
(ko)
|
2020-04-28 |
2023-02-06 |
인텔리아 테라퓨틱스, 인크. |
시험관내 세포 전달 방법
|
|
CA3179420A1
(en)
|
2020-05-20 |
2021-11-25 |
Avak Kahvejian |
Coronavirus antigen compositions and their uses
|
|
IL298363A
(en)
|
2020-05-20 |
2023-01-01 |
Flagship Pioneering Innovations Vi Llc |
Immunogenic compositions and uses thereof
|
|
JP2023526533A
(ja)
|
2020-05-22 |
2023-06-21 |
ウェイブ ライフ サイエンシズ リミテッド |
二本鎖オリゴヌクレオチド組成物及びそれに関連する方法
|
|
CA3182026A1
(en)
|
2020-05-29 |
2021-12-02 |
Flagship Pioneering Innovations Vi, Llc. |
Trem compositions and methods relating thereto
|
|
CA3180101A1
(en)
|
2020-05-29 |
2021-12-02 |
Flagship Pioneering Innovations Vi, Llc |
Trem compositions and methods relating thereto
|
|
US20230234992A1
(en)
|
2020-06-05 |
2023-07-27 |
Glaxosmithkline Biologicals Sa |
Modified betacoronavirus spike proteins
|
|
EP4171629A1
(en)
|
2020-06-29 |
2023-05-03 |
GlaxoSmithKline Biologicals S.A. |
Adjuvants
|
|
WO2022016070A1
(en)
|
2020-07-16 |
2022-01-20 |
Acuitas Therapeutics, Inc. |
Cationic lipids for use in lipid nanoparticles
|
|
EP4185600A4
(en)
|
2020-07-24 |
2024-12-04 |
The General Hospital Corporation |
Enhanced virus-like particles and methods of use thereof for delivery to cells
|
|
MX2023002439A
(es)
|
2020-09-03 |
2023-05-09 |
Flagship Pioneering Innovations Vi Llc |
Composiciones immunogénicas y usos de las mismas.
|
|
AU2021342158A1
(en)
*
|
2020-09-11 |
2023-04-13 |
Arrowhead Pharmaceuticals, Inc. |
Lipid conjugates for the delivery of therapeutic agents
|
|
JP2023549011A
(ja)
|
2020-09-15 |
2023-11-22 |
ヴァーヴ・セラピューティクス，インコーポレーテッド |
遺伝子編集のための脂質製剤
|
|
CZ310613B6
(cs)
*
|
2020-09-23 |
2026-01-28 |
Ústav organické chemie a biochemie AV ČR, v. v. i. |
Lipidoidy pro transfekci nukleových kyselin a jejich použití
|
|
IL303195A
(en)
|
2020-11-25 |
2023-07-01 |
Akagera Medicines Inc |
Lipid nanoparticles for delivery of nucleic acids and related methods of use
|
|
CN113185421B
(zh)
*
|
2020-11-27 |
2022-01-25 |
广州市锐博生物科技有限公司 |
脂质化合物及其组合物
|
|
CR20230305A
(es)
|
2020-12-11 |
2023-11-10 |
Intellia Therapeutics Inc |
Polinucleótidos, composiciones y métodos para la edición del genoma que implican desaminación
|
|
IL303886A
(en)
|
2020-12-23 |
2023-08-01 |
Flagship Pioneering Inc |
Compositions of modified trems and uses thereof
|
|
EP4267593A2
(en)
|
2020-12-23 |
2023-11-01 |
GlaxoSmithKline Biologicals SA |
Self-amplifying messenger rna
|
|
AU2021411521A1
(en)
|
2020-12-30 |
2023-08-03 |
Intellia Therapeutics, Inc. |
Engineered t cells
|
|
IL303845A
(en)
|
2021-01-20 |
2023-08-01 |
Beam Therapeutics Inc |
Nanomaterials include a degradable property
|
|
KR20230131863A
(ko)
*
|
2021-01-20 |
2023-09-14 |
빔 테라퓨틱스, 인크. |
나노물질
|
|
EP4032546A1
(en)
|
2021-01-20 |
2022-07-27 |
GlaxoSmithKline Biologicals S.A. |
Therapeutic viral vaccine
|
|
JP2024503441A
(ja)
*
|
2021-01-20 |
2024-01-25 |
ビーム セラピューティクス インク． |
イオン化可能な脂質を含むナノ材料
|
|
CN113993839B
(zh)
*
|
2021-02-05 |
2024-02-09 |
嘉晨西海(杭州)生物技术有限公司 |
一种可离子化脂质分子、其制备方法及其在制备脂质纳米颗粒中的应用
|
|
CN112961065B
(zh)
*
|
2021-02-05 |
2023-03-14 |
嘉晨西海(杭州)生物技术有限公司 |
一种可电离脂质分子及其制备方法及其在制备脂质纳米颗粒的应用
|
|
US20240181037A1
(en)
|
2021-03-26 |
2024-06-06 |
Glaxosmithkline Biologicals Sa |
Immunogenic compositions
|
|
JP2024512669A
(ja)
|
2021-03-31 |
2024-03-19 |
フラグシップ パイオニアリング イノベーションズ ブイ，インコーポレーテッド |
タノトランスミッションポリペプチド及び癌の処置におけるそれらの使用
|
|
EP4321524B1
(en)
|
2021-04-09 |
2025-12-10 |
Sogo Pharmaceutical Co., Ltd. |
Lipid and composition
|
|
CR20230535A
(es)
|
2021-04-17 |
2024-02-16 |
Intellia Therapeutics Inc |
Inhibidores de proteína cinasa dependiente de adn y composiciones y usos de estos
|
|
BR112023021477A2
(pt)
|
2021-04-17 |
2024-01-30 |
Intellia Therapeutics Inc |
Composições de nanopartículas lipídicas
|
|
US20240200106A1
(en)
|
2021-04-17 |
2024-06-20 |
Intellia Thrapeutics, Inc. |
Lipid nanoparticles compositions
|
|
JP2024526021A
(ja)
*
|
2021-05-24 |
2024-07-17 |
ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア |
核酸のための１成分送達系
|
|
EP4346894A1
(en)
|
2021-05-24 |
2024-04-10 |
GlaxoSmithKline Biologicals S.A. |
Adjuvants
|
|
EP4352247A1
(en)
|
2021-06-09 |
2024-04-17 |
GlaxoSmithKline Biologicals s.a. |
Release assay for determining potency of self-amplifying rna drug product and methods for using
|
|
KR20240032013A
(ko)
|
2021-06-10 |
2024-03-08 |
인텔리아 테라퓨틱스, 인크. |
유전자 편집을 위한 내부 링커를 포함하는 변형된 가이드 rna
|
|
US20250127809A1
(en)
|
2021-06-23 |
2025-04-24 |
Novartis Ag |
Compositions and methods for the treatment of hemoglobinopathies
|
|
WO2023009547A1
(en)
|
2021-07-26 |
2023-02-02 |
Flagship Pioneering Innovations Vi, Llc |
Trem compositions and uses thereof
|
|
WO2023021427A1
(en)
|
2021-08-16 |
2023-02-23 |
Glaxosmithkline Biologicals Sa |
Freeze-drying of lipid nanoparticles (lnps) encapsulating rna and formulations thereof
|
|
WO2023020992A1
(en)
|
2021-08-16 |
2023-02-23 |
Glaxosmithkline Biologicals Sa |
Novel methods
|
|
WO2023020994A1
(en)
|
2021-08-16 |
2023-02-23 |
Glaxosmithkline Biologicals Sa |
Novel methods
|
|
WO2023021421A1
(en)
|
2021-08-16 |
2023-02-23 |
Glaxosmithkline Biologicals Sa |
Low-dose lyophilized rna vaccines and methods for preparing and using the same
|
|
WO2023020993A1
(en)
|
2021-08-16 |
2023-02-23 |
Glaxosmithkline Biologicals Sa |
Novel methods
|
|
JP2024534915A
(ja)
|
2021-09-03 |
2024-09-26 |
グラクソスミスクライン バイオロジカルズ ソシエテ アノニム |
自己増幅性メッセンジャーリボ核酸におけるヌクレオチド塩基の置換
|
|
JP2024533311A
(ja)
|
2021-09-08 |
2024-09-12 |
フラッグシップ パイオニアリング イノベーションズ シックス，エルエルシー |
ゲノムを調節するための方法及び組成物
|
|
ES2994006T3
(en)
|
2021-09-17 |
2025-01-16 |
Flagship Pioneering Innovations Vi Llc |
Compositions and methods for producing circular polyribonucleotides
|
|
JP2024538144A
(ja)
|
2021-10-18 |
2024-10-18 |
フラッグシップ パイオニアリング イノベーションズ シックス，エルエルシー |
ポリリボヌクレオチドを精製するための組成物及び方法
|
|
EP4423271A2
(en)
|
2021-10-28 |
2024-09-04 |
Regeneron Pharmaceuticals, Inc. |
Crispr/cas-related methods and compositions for knocking out c5
|
|
EP4426822A2
(en)
|
2021-11-03 |
2024-09-11 |
Intellia Therapeutics, Inc. |
Polynucleotides, compositions, and methods for genome editing
|
|
EP4430024A1
(en)
|
2021-11-08 |
2024-09-18 |
Orna Therapeutics, Inc. |
Lipid nanoparticle compositions for delivering circular polynucleotides
|
|
EP4436984A1
(en)
|
2021-11-24 |
2024-10-02 |
Flagship Pioneering Innovations VI, LLC |
Coronavirus immunogen compositions and their uses
|
|
AU2022397292A1
(en)
|
2021-11-24 |
2024-05-30 |
Flagship Pioneering Innovations Vi, Llc |
Varicella-zoster virus immunogen compositions and their uses
|
|
MX2024006440A
(es)
|
2021-11-24 |
2024-08-19 |
Flagship Pioneering Innovations Vi Llc |
Composiciones inmunogenicas y sus usos.
|
|
WO2023102364A1
(en)
*
|
2021-12-02 |
2023-06-08 |
Ecole Polytechnique Federale De Lausanne (Epfl) |
Antiviral compounds, compositions and uses thereof
|
|
US20250223584A2
(en)
|
2021-12-03 |
2025-07-10 |
The Broad Institute, Inc. |
Compositions and methods for efficient in vivo delivery
|
|
KR20240117149A
(ko)
|
2021-12-22 |
2024-07-31 |
플래그쉽 파이어니어링 이노베이션스 브이아이, 엘엘씨 |
폴리리보뉴클레오티드를 정제하기 위한 조성물 및 방법
|
|
MX2024007870A
(es)
|
2021-12-23 |
2024-08-15 |
Flagship Pioneering Innovations Vi Llc |
Polirribonucleotidos circulares que codifican polipeptidos antifusogenicos.
|
|
WO2023148303A1
(de)
*
|
2022-02-02 |
2023-08-10 |
Mslsolutions Gmbh |
Verfahren zur medikament- und impfstoffherstellung
|
|
EP4473103A2
(en)
|
2022-02-02 |
2024-12-11 |
Regeneron Pharmaceuticals, Inc. |
Anti-tfr:gaa and anti-cd63:gaa insertions for treatment of pompe disease
|
|
JP2023130120A
(ja)
*
|
2022-03-07 |
2023-09-20 |
スペラファーマ株式会社 |
ペプチド合成方法
|
|
WO2023178065A2
(en)
*
|
2022-03-15 |
2023-09-21 |
Broadpharm Inc. |
Lipid compounds and lipid nanoparticles
|
|
EP4499607A1
(en)
*
|
2022-03-25 |
2025-02-05 |
Sail Biomedicines, Inc. |
Novel ionizable lipids and lipid nanoparticles and methods of using the same
|
|
JP2025511756A
(ja)
|
2022-04-08 |
2025-04-16 |
フラッグシップ パイオニアリング イノベーションズ セブン，エルエルシー |
ワクチン及び関連する方法
|
|
US20250295687A1
(en)
|
2022-05-09 |
2025-09-25 |
Flagship Pioneering Innovations Vi, Llc |
Trem compositions and methods of use for treating proliferative disorders
|
|
US20250302998A1
(en)
|
2022-05-09 |
2025-10-02 |
Regeneron Pharmaceuticals, Inc. |
Vectors and methods for in vivo antibody production
|
|
JP2025516638A
(ja)
|
2022-05-13 |
2025-05-30 |
フラッグシップ パイオニアリング イノベーションズ セブン，エルエルシー |
二本鎖ｄｎａ組成物及び関連する方法
|
|
CN120303407A
(zh)
|
2022-05-17 |
2025-07-11 |
恩维洛普治疗有限责任公司 |
用于有效体内递送的组合物和方法
|
|
CN119384498A
(zh)
|
2022-06-16 |
2025-01-28 |
因特利亚治疗公司 |
用于对细胞进行遗传修饰的方法和组合物
|
|
WO2023242817A2
(en)
|
2022-06-18 |
2023-12-21 |
Glaxosmithkline Biologicals Sa |
Recombinant rna molecules comprising untranslated regions or segments encoding spike protein from the omicron strain of severe acute respiratory coronavirus-2
|
|
US20250179492A1
(en)
|
2022-06-22 |
2025-06-05 |
Flagship Pioneering Innovations Vi, Llc |
Compositions of modified trems and uses thereof
|
|
CN119585419A
(zh)
|
2022-06-29 |
2025-03-07 |
因特利亚治疗公司 |
工程化t细胞
|
|
CN117486738B
(zh)
*
|
2022-07-15 |
2025-08-12 |
中国科学院基础医学与肿瘤研究所(筹) |
一种脂质分子及其组合物
|
|
WO2024019936A1
(en)
|
2022-07-20 |
2024-01-25 |
Beam Therapeutics Inc. |
Nanomaterials comprising triols
|
|
IL318625A
(en)
|
2022-07-29 |
2025-03-01 |
Regeneron Pharma |
Compositions and methods for transferrin receptor (TFR)-mediated delivery to brain and muscle
|
|
JP2025525778A
(ja)
|
2022-08-01 |
2025-08-07 |
フラッグシップ パイオニアリング イノベーションズ セブン，エルエルシー |
免疫調節タンパク質及び関連方法
|
|
EP4569112A1
(en)
|
2022-08-12 |
2025-06-18 |
Remix Therapeutics Inc. |
Methods and compositions for modulating splicing at alternative splice sites
|
|
CN119947747A
(zh)
|
2022-09-26 |
2025-05-06 |
葛兰素史克生物有限公司 |
流感病毒疫苗
|
|
WO2024077191A1
(en)
|
2022-10-05 |
2024-04-11 |
Flagship Pioneering Innovations V, Inc. |
Nucleic acid molecules encoding trif and additionalpolypeptides and their use in treating cancer
|
|
AU2023372397A1
(en)
|
2022-10-31 |
2025-05-08 |
Flagship Pioneering Innovations Vi, Llc |
Compositions and methods for purifying polyribonucleotides
|
|
IL320016A
(en)
|
2022-11-04 |
2025-06-01 |
Regeneron Pharma |
Calcium voltage-gated channel auxiliary subunit gamma 1 (cacng1) binding proteins and cacng1-mediated delivery to skeletal muscle
|
|
EP4615465A1
(en)
|
2022-11-08 |
2025-09-17 |
Flagship Pioneering Innovations VI, LLC |
Compositions and methods for producing circular polyribonucleotides
|
|
CN120390656A
(zh)
|
2022-11-08 |
2025-07-29 |
欧纳医疗公司 |
环状rna组合物
|
|
WO2024102762A1
(en)
|
2022-11-08 |
2024-05-16 |
Orna Therapeutics, Inc. |
Lipids and lipid nanoparticle compositions for delivering polynucleotides
|
|
TW202425959A
(zh)
|
2022-11-08 |
2024-07-01 |
美商歐納醫療公司 |
遞送多核苷酸的脂質及奈米顆粒組合物
|
|
AU2023379457A1
(en)
|
2022-11-14 |
2025-05-15 |
Regeneron Pharmaceuticals, Inc. |
Compositions and methods for fibroblast growth factor receptor 3-mediated delivery to astrocytes
|
|
TW202430215A
(zh)
|
2022-12-14 |
2024-08-01 |
美商旗艦先鋒創新有限責任（Ｖｉｉ）公司 |
用於將治療劑遞送至骨之組成物和方法
|
|
AU2023398825A1
(en)
|
2022-12-15 |
2025-06-26 |
Orna Therapeutics, Inc. |
Circular rna compositions and methods
|
|
WO2024133160A1
(en)
|
2022-12-19 |
2024-06-27 |
Glaxosmithkline Biologicals Sa |
Hepatitis b compositions
|
|
WO2024138189A2
(en)
|
2022-12-22 |
2024-06-27 |
Intellia Therapeutics, Inc. |
Methods for analyzing nucleic acid cargos of lipid nucleic acid assemblies
|
|
WO2024138115A1
(en)
|
2022-12-23 |
2024-06-27 |
Intellia Theraperutics, Inc. |
Systems and methods for genomic editing
|
|
WO2024151583A2
(en)
|
2023-01-09 |
2024-07-18 |
Flagship Pioneering Innovations Vii, Llc |
Vaccines and related methods
|
|
US20240252520A1
(en)
|
2023-01-09 |
2024-08-01 |
Beth Israel Deaconess Medical Center, Inc. |
Therapeutic agents and their use for treating chronic wounds
|
|
US20240238473A1
(en)
|
2023-01-09 |
2024-07-18 |
Beth Israel Deaconess Medical Center, Inc. |
Recombinant nucleic acid molecules and their use in wound healing
|
|
WO2024151687A1
(en)
|
2023-01-09 |
2024-07-18 |
Flagship Pioneering Innovations V, Inc. |
Genetic switches and their use in treating cancer
|
|
WO2024160936A1
(en)
|
2023-02-03 |
2024-08-08 |
Glaxosmithkline Biologicals Sa |
Rna formulation
|
|
WO2024167885A1
(en)
|
2023-02-06 |
2024-08-15 |
Flagship Pioneering Innovations Vii, Llc |
Immunomodulatory compositions and related methods
|
|
IL322468A
(en)
|
2023-02-13 |
2025-09-01 |
Flagship Pioneering Innovations Vii Llc |
Ionizable lipids containing degradable crosslinkers and lipid carriers for therapeutic compositions
|
|
GB202302092D0
(en)
|
2023-02-14 |
2023-03-29 |
Glaxosmithkline Biologicals Sa |
Analytical method
|
|
IL322378A
(en)
|
2023-02-17 |
2025-09-01 |
Flagship Pioneering Innovations Vii Llc |
DNA compositions containing modified cytosine
|
|
JP2026507513A
(ja)
|
2023-02-17 |
2026-03-04 |
フラッグシップ パイオニアリング イノベーションズ セブン，エルエルシー |
修飾されたウラシルを含むｄｎａ組成物
|
|
EP4680276A1
(en)
|
2023-03-15 |
2026-01-21 |
Flagship Pioneering Innovations VI, LLC |
Immunogenic compositions and uses thereof
|
|
WO2024192420A1
(en)
|
2023-03-15 |
2024-09-19 |
Flagship Pioneering Innovations Vi, Llc |
Compositions comprising polyribonucleotides and uses thereof
|
|
WO2024205657A2
(en)
|
2023-03-29 |
2024-10-03 |
Orna Therapeutics, Inc. |
Lipids and lipid nanoparticle compositions for delivering polynucleotides
|
|
WO2024216191A1
(en)
|
2023-04-12 |
2024-10-17 |
Flagship Pioneering Innovations Vi, Llc |
Modified trems, compositions, and related methods thereof
|
|
WO2024216128A1
(en)
|
2023-04-12 |
2024-10-17 |
Flagship Pioneering Innovations Vi, Llc |
Trems for use in correction of missense mutations
|
|
WO2024220746A2
(en)
|
2023-04-21 |
2024-10-24 |
Flagship Pioneering Innovations Vii, Llc |
Rnai agents targeting fatty acid synthase and related methods
|
|
EP4701658A1
(en)
|
2023-04-27 |
2026-03-04 |
GlaxoSmithKline Biologicals S.A. |
Influenza virus vaccines
|
|
WO2024223724A1
(en)
|
2023-04-27 |
2024-10-31 |
Glaxosmithkline Biologicals Sa |
Influenza virus vaccines
|
|
WO2024233308A2
(en)
|
2023-05-05 |
2024-11-14 |
Orna Therapeutics, Inc. |
Circular rna compositions and methods
|
|
TW202502729A
(zh)
|
2023-05-19 |
2025-01-16 |
美商英特利亞醫療公司 |
可電離胺脂質
|
|
WO2024258829A1
(en)
|
2023-06-12 |
2024-12-19 |
Flagship Pioneering Innovations Vii, Llc |
Sars-cov-2 vaccine compositions and related methods
|
|
WO2025006684A1
(en)
|
2023-06-28 |
2025-01-02 |
Flagship Pioneering Innovations Vi, Llc |
Circular polyribonucleotides encoding antifusogenic polypeptides
|
|
CN116535381B
(zh)
*
|
2023-07-06 |
2023-10-17 |
北京悦康科创医药科技股份有限公司 |
具有五元环缩醛结构的阳离子脂质化合物、包含其的组合物及用途
|
|
WO2025011529A2
(en)
|
2023-07-07 |
2025-01-16 |
Shanghai Circode Biomed Co., Ltd. |
Circular rna vaccines for seasonal flu and methods of uses
|
|
AU2024299627A1
(en)
|
2023-07-25 |
2026-01-22 |
Flagship Pioneering Innovations Vii, Llc |
Cas endonucleases and related methods
|
|
AU2024315073A1
(en)
|
2023-07-28 |
2026-01-22 |
Regeneron Pharmaceuticals, Inc. |
Use of bgh-sv40l tandem polya to enhance transgene expression during unidirectional gene insertion
|
|
US20250049896A1
(en)
|
2023-07-28 |
2025-02-13 |
Regeneron Pharmaceuticals, Inc. |
Anti-tfr:acid sphingomyelinase for treatment of acid sphingomyelinase deficiency
|
|
WO2025042786A1
(en)
|
2023-08-18 |
2025-02-27 |
Flagship Pioneering Innovations Vi, Llc |
Compositions comprising circular polyribonucleotides and uses thereof
|
|
WO2025049481A1
(en)
|
2023-08-28 |
2025-03-06 |
Intellia Therapeutics, Inc. |
Methods of editing an hla-a gene in vitro
|
|
CN121752588A
(zh)
|
2023-08-29 |
2026-03-27 |
上海环码生物医药有限公司 |
编码vegf多肽的环状rna、制剂和使用方法
|
|
WO2025054236A2
(en)
|
2023-09-06 |
2025-03-13 |
Flagship Pioneering Innovations Vii, Llc |
Sars-cov-2 vaccine compositions and related methods
|
|
AU2024344058A1
(en)
|
2023-09-18 |
2026-04-02 |
Flagship Pioneering Innovations Vii, Llc |
Ionizable lipidoid compositions and therapeutic uses thereof
|
|
WO2025072331A1
(en)
|
2023-09-26 |
2025-04-03 |
Flagship Pioneering Innovations Vii, Llc |
Cas nucleases and related methods
|
|
WO2025096807A2
(en)
|
2023-10-31 |
2025-05-08 |
Flagship Pioneering Innovations Vii, Llc |
Novel therapeutic dna forms
|
|
WO2025101501A1
(en)
|
2023-11-07 |
2025-05-15 |
Orna Therapeutics, Inc. |
Circular rna compositions
|
|
WO2025106670A1
(en)
|
2023-11-14 |
2025-05-22 |
Flagship Pioneering Innovations Vii, Llc |
Ionizable lipidoid compositions and therapeutic uses thereof
|
|
US20250161347A1
(en)
|
2023-11-22 |
2025-05-22 |
Flagship Pioneering Innovations Vii, Llc |
Methods and compositions for treating non-alcoholic fatty liver disease
|
|
WO2025117732A1
(en)
*
|
2023-11-29 |
2025-06-05 |
Akagera Medicines, Inc. |
Lipid nanoparticles for delivery of nucleic acids and methods of use thereof
|
|
WO2025117877A2
(en)
|
2023-12-01 |
2025-06-05 |
Flagship Pioneering Innovations Vii, Llc |
Cas nucleases and related methods
|
|
WO2025137439A2
(en)
|
2023-12-20 |
2025-06-26 |
Intellia Therapeutics, Inc. |
Engineered t cells
|
|
WO2025137301A1
(en)
|
2023-12-20 |
2025-06-26 |
Intellia Therapeutics, Inc. |
Methods for rapid engineering of cells
|
|
WO2025132839A1
(en)
|
2023-12-21 |
2025-06-26 |
Glaxosmithkline Biologicals Sa |
Influenza virus vaccines
|
|
TW202545974A
(zh)
|
2024-01-26 |
2025-12-01 |
美商旗艦先鋒創新有限責任（Ｖｉｉ）公司 |
免疫受體抑制蛋白及相關方法
|
|
WO2025160340A2
(en)
|
2024-01-26 |
2025-07-31 |
Regeneron Pharmaceuticals, Inc. |
Combination immunosuppression for inhibiting an immune response and enabling immunogen administration and re-administration
|
|
WO2025194019A1
(en)
|
2024-03-14 |
2025-09-18 |
Flagship Pioneering Innovations Vii, Llc |
Methods for treating liver fibrosis and non-alcoholic fatty liver disease
|
|
GB202404607D0
(en)
|
2024-03-29 |
2024-05-15 |
Glaxosmithkline Biologicals Sa |
RNA formulation
|
|
WO2025217275A2
(en)
|
2024-04-10 |
2025-10-16 |
Flagship Pioneering Innovations Vii, Llc |
Immune cell targeted compositions and related methods
|
|
WO2025229572A1
(en)
|
2024-05-01 |
2025-11-06 |
Glaxosmithkline Biologicals Sa |
Epstein-barr virus antigen-encoding messenger ribonucleic acid and antigen protein vaccines
|
|
WO2025240680A1
(en)
|
2024-05-16 |
2025-11-20 |
Flagship Pioneering Innovations Vii, Llc |
Immunoreceptor inhibitory proteins and related methods
|
|
WO2025240946A1
(en)
|
2024-05-17 |
2025-11-20 |
Intellia Therapeutics, Inc. |
Lipid nanoparticles and lipid nanoparticle compositions
|
|
WO2025245188A2
(en)
|
2024-05-21 |
2025-11-27 |
Flagship Pioneering Innovations Vii, Llc |
Methods of treating liver steatosis and non-alcoholic fatty liver disease
|
|
WO2025245111A1
(en)
|
2024-05-22 |
2025-11-27 |
Flagship Pioneering Innovations Vii, Llc |
Immunoreceptor targeting proteins and related methods
|
|
WO2025265017A1
(en)
|
2024-06-20 |
2025-12-26 |
Regeneron Pharmaceuticals, Inc. |
Ass1 gene insertion for the treatment of citrullinemia type i
|
|
US20260000702A1
(en)
|
2024-06-26 |
2026-01-01 |
Flagship Pioneering Innovations Vii, Llc |
Therapeutic circular dna forms
|
|
WO2026055547A1
(en)
|
2024-09-06 |
2026-03-12 |
Flagship Pioneering Innovations Vii, Llc |
Dna compositions and related methods
|
|
WO2026055543A1
(en)
|
2024-09-06 |
2026-03-12 |
Flagship Pioneering Innovations Vii, Llc |
Modified dna compositions and related methods
|
|
WO2026064313A1
(en)
|
2024-09-17 |
2026-03-26 |
Flagship Pioneering Innovations Vii, Llc |
Rna compositions and related methods
|
|
CN119462481B
(zh)
*
|
2025-01-17 |
2025-04-25 |
北京悦康科创医药科技股份有限公司 |
Sting激活型佐剂脂质、包含其的组合物及用途
|